David M. Nanus

Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN.

Aminopeptidase A is a functional target in angiogenic blood vessels.

Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.

Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens.

Synergistic activation of the androgen receptor by bombesin and low-dose androgen.

Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?

The utility of monoclonal antibodies in the imaging of prostate cancer.

Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.

High expression of the Met receptor in prostate cancer metastasis to bone.

Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase.

Chemotherapeutic strategies for renal cell carcinoma.

Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.

Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.

Of peptides and peptidases: the role of cell surface peptidases in cancer.

Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins.

Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase.

Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Neutral endopeptidase protein expression and prognosis in localized prostate cancer.

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.

Retinoid receptor mRNA expression profiles in human bladder cancer specimens.

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

Involvement of neutral endopeptidase in neoplastic progression.

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.

Antibody-based therapeutics: focus on prostate cancer.

Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

Chemotherapy for non-clear-cell renal cell carcinoma.

Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.

Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter.

Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma.

Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway.

Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.

Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells.

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.

Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.

Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.

Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.

Rational redesign of neutral endopeptidase binding to merlin and moesin proteins.

Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model.

Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.

Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations.

Neutral endopeptidase is a myristoylated protein.

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature.

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.

Is methylation the key to CD10 loss?

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.

Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.

Recent advances in management of renal cancer.

Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007).

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.

Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Androgen receptor on the move: boarding the microtubule expressway to the nucleus.

Isolation and characterization of circulating tumor cells in prostate cancer.

Negative regulation of NEP expression by hypoxia.

Challenges in recognizing treatment-related neuroendocrine prostate cancer.

2-weekly versus 3-weekly docetaxel for prostate cancer.

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Immunologics and Chemotherapeutics for Renal Cell Carcinoma.

Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential.